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Abstract
Topical mometasone is frequently used as an intranasal spray, on drug eluting stents, and 
compounded by specialty pharmacies as a sinus rinse. A typical sinus rinse contains 1.2 mg of 
mometasone dissolved in 240 mL of buffered saline and is flushed through the sinonasal cavity. 
The mometasone irrigation rapidly flows to the contralateral sinonasal cavity or the nasopharynx 
with a contact time on the order of 5–10 seconds. However, no information is available on the 
absorption rate of topical mometasone on the sinonasal surface. To determine the absorption 
characteristics of mometasone, we harvested nasal epithelium from 2 healthy donors and 
differentiated them into a mature ciliated epithelium on Millicell membranes. We applied 
mometasone to the apical surface at various time points and then rinsed off non-absorbed 
mometasone with phosphate buffered saline. Millicell membranes with the adherent epithelial 
cells were then harvested and stored in guanidine hydrochloride for quantification using a high-
performance liquid chromatography-mass spectrometry method. Fifty percent of the maximal 
absorption occurred 37.8 minutes after application, and maximal absorption occurred after 2 
hours. Our data provide an estimate for rates of absorption of mometasone applied to the sinonasal 
cavity and suggest that the absorption rates poorly match contact time during saline lavage.
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Chronic rhinosinusitis (CRS) is defined as symptomatic inflammation of the sinonasal cavity 
for more than 12 weeks and is a clinical diagnosis based on the presence of 2 of the 
following symptoms: mucopurulent drainage, nasal obstruction, facial pain/pressure/fullness 
or decreased sense of smell, in addition to purulent mucus, nasal polyps, or radiographic 
evidence of mucosal inflammation.1,2 Recent evaluations of the medical and socioeconomic 
impacts of CRS estimate that the disease affects 2–16% of the US population and has an 
economic burden of greater than $60 billion annually.3 Sinusitis accounts for nearly 5% of 
overall US health care expenditures.3
In addition to the financial implications, CRS substantially decreases quality of life, in a 
magnitude similar to or exceeding that experienced by patients with Parkinson’s disease, 
congestive heart failure, or chronic obstructive pulmonary disease.4 Despite the substantial 
burden of CRS, sufficient treatment options have yet to be identified.
Modern molecular-based therapies for CRS are lagging behind therapies for other airway 
diseases such as cystic fibrosis (CF) and asthma. For people with asthma, multiple immune 
modulators have come to market and more are in the drug discovery pipeline.5 In CF, 
targeting apical ion channels has been shown to decrease disease burden and is hoped to 
increase life expectancy.6 Despite these advances in lower airway diseases, little progress 
has been made in the medical management of CRS, which still relies on antibiotics and 
corticosteroids.
Corticosteroids are used to decrease inflammation and suppress the adaptive immune 
response.7 Clinical trials have demonstrated symptomatic improvement in patients with CRS 
with nasal polyps while on oral steroids.8 However, oral administration of steroids can result 
in severe adverse effects, including hyperglycemia, mania, glaucoma, cataracts, 
osteoporosis, and avascular necrosis of the femoral head.9
Topical administration of corticosteroids via spray or lavage theoretically provides the 
benefits of steroids with fewer adverse effects. Of the currently approved intranasal 
corticosteroid sprays, only mometasone furoate (Nasonex; Merck, Kenilworth, NJ) is 
specifically approved for chronic sinusitis. Despite the indication for CRS, topical sprays 
have poor penetration in the sinuses, and deposition of spray-based intranasal steroids occurs 
primarily on the inferior turbinate and internal valve. 10 Because of the poor penetration of 
nasal sprays into the sinuses, many clinicians use high-volume steroid rinses formulated by 
compounding pharmacies. Although this treatment is not approved by the Food and Drug 
Administration, numerous studies have shown benefit of corticosteroid-containing rinses,
11–13 and a recent double-blind, randomized control trial demonstrated improved symptoms 
from mometasone rinses compared with mometasone nasal spray in the postoperative 
setting.14
Mometasone furoate has high affinity for the glucocorticoid receptor and has minimal 
systemic absorption.15 It is highly lipophilic, which helps facilitate absorption into the 
epithelium and has a low systemic bioavailability, which is desired to reduce systemic side 
effects.16 Mometasone furoate has an estimated systemic bioavailability of <1% while 
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fluticasone propionate has a systemic bioavailability of ~17%.17 These properties make 
mometasone furoate ideal for topical sinonasal application, and it is one of the most 
commonly used steroids for saline lavage.
While it is understood that a significant portion of the medication will flow through the 
sinonasal cavity and be lost to the drain, the rate of absorption of mometasone on the 
sinonasal epithelium is unknown. We developed a high-performance liquid chromatography 
(HPLC)-mass spectrometry (MS) method to quantitatively determine the amount of 
mometasone absorbed in the cultured airway epithelium.
METHODS:
Human Nasal Epithelial Air-Liquid Interface (ALI) Cultures:
A middle turbinate (donor 1) that was excised as part of a transsphenoidal approach was 
obtained from a patient with no evidence of inflammatory sinus disease using IRB protocols 
#03–1396. Curettage (donor 2) of the inferior turbinate was performed to obtain second 
nasal epithelia cell line from a healthy donor using IRB protocols #98–1015.
The middle turbinate was processed overnight in 0.1% protease XIV and DNAse solution. 
Protease was neutralized with fetal bovine serum (Sigma Aldrich; St. Louis, MO), and the 
turbinate was then scraped using a scalpel to isolate human nasal epithelial cells (HNECs). 
Cells were pelleted, counted, and expanded using the conditionally reprogrammed cell 
(CRC) method as previously described.18,19 After expanding for one passage, cells were 
plated onto 12-mm diameter Millicell CM inserts (Millipore; Burlington, MA) at a density 
of 250,000 cells per insert.20
The inferior turbinate underwent curettage, and cells were pelleted, counted, and expanded 
using the CRC method as previously described. 18,19 After expansion, cells were passed and 
plated onto 12-mm diameter Millicell CM inserts at a density of 250,000 cells per insert.20
HNECs were washed with 1X phosphate buffered saline (PBS) and fed with ALI media19 
apically and basal-laterally for approximately 3 days. Once cells reached 90% confluence, 
they were only fed basal laterally to create an ALI culture, therefore facilitating 
differentiation into a mature ciliated epithelium (Figure 1). HNEC cultures were maintained 
until day 28 and then treated with mometasone or utilized for histology.
Mometasone Treatment:
Mometasone was diluted to 1.2 mg/240 mL in buffered saline (Standard Neil-Med packet in 
distilled H2O). HNECs were treated with 200 μL of mometasone solution for the indicated 
times. The mometasone exposure was stopped by washing the apical and basal surface of the 
membrane 3 times with PBS (200 μl apically and 1 mL on the basal surface). Membrane 
inserts were excised and placed in 200 μL of guanidine hydrochloride (6M). To ensure lysis, 
3 freeze-thaw cycles were performed.
Membrane inserts without HNECs were treated with mometasone and incubated for 24 
hours prior to washing exactly as in the experimental group.
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Mature HNEC ALI cultures were either washed three times with PBS then fixed in 4% 
paraformaldehyde or fixed without washing (unwashed; Figure 4). Cells were then 
permeabilized and blocked. Slides were made from these cell blocks. The slides were then 
incubated in primary antibodies against MUC5AC (45M1, ThermoFisher; Waltham, MC) 
and MUC5B (in-house rabbit anti-human polyclonal antibody). After washing, slides were 
incubated with appropriate fluorescent secondary antibodies (Jackson ImmunoResearch; 
Westgrove, PA) and chemical stains for filamentous actin (phalloidin) and nuclei (Hoechst).
Four single-layer x-y images of the apical surfaces of each condition were acquired in 
triplicate with an Olympus Fluoview 1000 microscope with a 60X oil objective. ImageJ20 
software was used to process images and quantify mucin.21 MUC5AC and MUC5B were 
quantified using ImageJ and normalized to the unwashed Millicells (Figure 4).
HPLC-MS/MS Sample Preparation:
Lysed cells were treated with 25 μL of 200 ng/mL mometasone furoate-d3 internal standard 
(IS) and vortexed for 15 s. One mL of methyl tert-butyl ether (MTBE) was added to each 
sample, and all samples were shaken for 30 min. Samples were centrifuged for 5 min at 
5,000 rpm. The supernatant MTBE layer was collected and evaporated under vacuum. The 
extract was reconstituted in 200 μL of methanol, vortexed, and transferred to an auto-
sampler vial.
HPLC-MS/MS Parameters:
Gradient-programmed mobile phase delivery was performed with Shimadzu LC-20AD 
HPLC pumps, and chromatographic separations were carried out on an Atlantis T3 C18 
column (3 μm, 2.1 × 50 mm; Waters Corporation, Milford, MA) maintained at 40˚C. A 
mobile phase flow rate of 0.3 mL/min was used. Mobile phase A was water (Optima LC-MS 
grade; Fisher Scientific, Fair Lawn, NJ) with 0.1% formic acid, and mobile phase B was 
acetonitrile (Optima LC-MS grade; Fisher Scientific, Fair Lawn, NJ) with 0.1% formic acid. 
The gradient program was mobile phase B, 40% (0 min), 80% (5 min), 95% (5.1–6 min), 
40% (6.1–10 min). An injection volume of 10 μL was used for all samples, calibrators, and 
quality control (QC) samples. HPLC was coupled to the electrospray ionization (ESI) source 
of a PESciex 3000 triple quadrupole mass spectrometer. ESI voltage was set to +4 kV, 
nitrogen was used as the nebulizing gas (10 arb units), and the source was held constant at 
400 ˚C. The mass spectrometer was operated in multiple-reaction monitoring (MRM) mode 
with nitrogen collision gas (10 arb units). The de-clustering potential was 62 V for all MRM 
transitions. One quantifying and 2 qualifying MRM transitions were monitored for both 
analyte and IS, each with a dwell time of 50 ms equating to a cycle time of 0.33 s. For 
mometasone furoate, the precursor ion to product ion transitions were m/z 521 → m/z 503 
(Quantifying, Collision Energy = 15 V), m/z 355 (Qualifying, CE = 21), and m/z 279 
(Qualifying, CE = 26). For mometasone furoate-d3, the precursor ion to product ion 
transitions were m/z 524 → m/ z 506 (Quantifying, Collision Energy = 15 V), m/z 355 
(Qualifying, CE = 30), and m/z 279 (Qualifying, CE = 26). Stock solutions of mometasone 
furoate and mometasone furoate-d3 were prepared in methanol (Optima LC-MS grade; 
Fisher Scientific, Fair Lawn, NJ). Six calibrators ranging from 1.5 to 100 ng/mL and QCs 
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were prepared in methanol, and 25 ng/mL IS was added to match the final IS concentration 
in samples (Figure 1). Any samples outside of the dilution range were diluted, and a dilution 
factor was applied to determine the concentration.
Data Analysis:
Time of 50% maximal absorption was calculated by non-linear regression assuming one 
site-specific binding (Prism 7; GraphPad Software, Inc)
RESULTS:
Using the method we developed, we were able to detect mometasone to quantities below 1 
ng (Figure 2) with a high signal to noise ratio. Upon application of mometasone, 50% 
maximal binding occurred in donor 1 and donor 2 at 35.6 min (95% CI 20.3 – 63.1 min) and 
40.0 min (95% CI 22.4 – 72.5 min) respectively. Maximal mometasone absorption in cells 
derived from donor 1 was 193.4 ng/mL (95% CI 154.7–258.1 ng/mL) and 221 ng/mL (95% 
CI 174 304.5 ng/mL) in donor 2 (Figure 3). After 107 minutes in donor 1 and 120 minutes in 
donor 2, 75% of the maximal mometasone was absorbed. In the first 30 seconds of contact 
only, 2.6% and 2.7% of the maximal absorption of mometasone occurred in donor 1 and 
donor 2, respectively. After 300 minutes of incubation with the mometasone solution, 
membrane controls had undetectable mometasone (Figure 3).
To determine whether mometasone binds non-specifically to the mucus layer of the cells, we 
quantified MUC5AC and MUC5B before washing the apical and basal surfaces 3 times with 
PBS (200 μL apically and 1 mL on the basal surface; Figure 4).Mucus was significantly 
decreased (p = 0.031) from 100% (SEM 14.96%) in unwashed HNECs to 1.804% (SEM 
1.028%) in washed HNECs.
DISCUSSION:
Using a robust HPLC-MS/MS assay with an in vitro airway epithelial model, we were able 
to determine the quantity of mometasone within the airway epithelium. Our data show that 
mometasone is not instantly absorbed into the epithelium. In the 2 HNEC cell lines derived 
from different healthy donors, half of the maximal absorption occurred at an average of 37.8 
minutes of contact, and 75% maximal absorption is not reached until after approximately 2 
hours of contact. , Only 2.7% of maximal mometasone absorption is achieved during the 
initial 30 seconds of contact. By contrast, The primary bolus of a nasal rinse contacts the 
sinonasal surface for 5–10 seconds, a time-frame that does not allow the majority of 
mometasone to be absorbed into the epithelium
Our findings do not dispute the clinical benefits of mometasone rinses; however, they 
highlight the different time scales of mometasone rinse versus absorption. It is possible that 
a thin coating of mometasone and pooling of the rinse in surgically opened sinuses allows 
for substantial absorption over a much longer time period. It is also possible that a severely 
inflamed mucosa absorbs mometasone at a faster rate than our in vitro model.
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Clinical benefits are noted with mometasone rinses, even with the kinetic discrepancy we 
have described. These findings suggest that if corticosteroid absorption during a sinonasal 
rinse were optimized, the clinical effects could be significantly enhanced with less drug. 
Furthermore, our study characterized a new HPLC-MS/MS method to quantify mometasone 
in cells that could be applied to nasal tissue to determine the physiological deposition of 
mometasone after topical sprays or irrigations in patients.
CONCLUSION:
This study demonstrates that the rate of mometasone absorption in epithelial tissue is 
dramatically longer than the contact time in a typical saline lavage. While we do not dispute 
the clinical results of mometasone irrigation and routinely utilize it in our patients, the 
methods developed here could be used to better understand the patterns of mometasone 
absorption in the sinonasal cavity and suggest that a corticosteroid with a better absorption 
profile may enhance the benefits for patients.
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Airway epithelial cells were grown on a semi-permeable membrane and differentiated into a 
ciliated epithelium. The apical surface of the epithelial layer is exposed to air overlying 
mucus and cilia. The cells are differentiated on a semi-permeable membrane. Mometasone is 
applied to the apical surface to mimic lavage by sinus rinse.
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Calibration curve for mometasone furoate as measured by analyte to internal standard peak 
area ratios from HPLC-MS/MS analysis.
Nguyen et al. Page 9














Mometasone is absorbed slowly on airway epithelium. Mometasone was applied to the 
apical surface of ciliated epithelium for the indicated time on 2 separate human nasal 
epithelial cell lines derived from healthy donors. The amount of absorbed mometasone was 
then quantified using LC-MS/MS. Non-specific binding to a Millicell insert without 
overlying cells was also determined.
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Washing human nasal epithelial cells removes the majority of mucus. Overall mucus was 
estimated by staining washed and unwashed HNECs for MUC5AC and MUC5B. There was 
significantly less mucus (p = 0.0031) after washing, with approximately 98% of mucus 
removed.
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